Neurology Central

Treating neurodegenerative disease with tyrosine kinase inhibitors


Background. Neurodegenerative diseases include genetic and sporadic disorders associated with progressive nervous system dysfunction. There is no cure for neurodegenerative diseases to date. Some symptomatic management medicines exist with limited efficacy, but they do not slow down or halt neurodegenerative processes. Alzheimer’s disease and Parkinson’s disease (PD) are the two most common neurodegenerative diseases affecting an estimated 6.8 million individuals in the U.S. [1]. More than 30 million people currently suffer from these diseases worldwide [2]. Aging is a critical risk factor associated with neurodegenerative diseases and the number of people over 75 years of age will double in the U.S. by 2050 [3]. Neurodegenerative diseases will increase with the world’s aging population. The estimated socio-economic cost of Alzheimer’s disease in the U.S. is around $400 billion per year [4, 5], which is equivalent to the cost of all cancers combined. Effective treatment of neurodegenerative diseases is the largest unmet medical need in the more economically developed countries of the world.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.